Vanda's tasimelteon SET for mid-2013 US filing on PhIII sleep results in blind patients
This article was originally published in Scrip
Vanda Pharmaceuticals gained 18.9% on the Nasdaq on 18 December after the company said its oral melatonin receptor agonist tasimelteon showed a marked improvement compared with placebo in regulating circadian rhythms for people who are blind and have trouble sleeping in normal patterns - a condition known as non-24-hour disorder - in a Phase III clinical trial.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.